‘Patent opposition’ seeks to ensure millions of people left out of Gilead licensing deals can access affordable generics
26 February 2016
This blog is all about current FDA approved drugs to treat the hepatitis C virus (HCV) with a focus on treating HCV according to genotype, using information extracted from peer-reviewed journals, liver meetings/conferences, and interactive learning activities.
Risk Of Developing Liver Cancer After HCV Treatment
▼
Friday, February 26, 2016
Access: Patent challenge hearing on Gilead hepatitis C drug sofosbuvir starts in India
Access: Patent challenge hearing on Gilead hepatitis C drug sofosbuvir starts in India
‘Patent opposition’ seeks to ensure millions of people left out of Gilead licensing deals can access affordable generics
26 February 2016
New Delhi/New York – In proceedings that could have major implications for millions of people waiting for affordable access to a life-saving hepatitis C drug, the Indian Patent office this week will begin hearings to determine whether US pharmaceutical company Gilead Sciences deserves a patent for sofosbuvir, a hepatitis C drug for which the company currently charges US$1,000 per pill in the US.
‘Patent opposition’ seeks to ensure millions of people left out of Gilead licensing deals can access affordable generics
26 February 2016
No comments:
Post a Comment